Why the study?
Does lercanidipine provide antihypertensive efficacy and safety in patients with hypertension and coronary heart disease?
Does lercanidipine provide antihypertensive efficacy and safety in patients with hypertension and coronary heart disease?
Lercanidipine is an effective and safe third-generation calcium channel blocker for patients with comorbid hypertension and coronary heart disease.
Supports lercanidipine consideration in comorbid hypertension and CHD; leaves open need for dedicated RCTs.
Comorbidity of cardiovascular diseases reciprocally aggravates their course and induces the need to use safety and well-tolerated drugs. Pharmacological and pharmacokinetic properties of lercanidipine – the third-generation calcium channel blocker – are characterized by high lipophilicity and tissue selectivity. Clinical studies provide evidence of antihypertensive efficacy and safety of lercanidipine that is successfully used in patients with arterial hypertension and coronary heart disease.
No takes yet. Share an insight, caveat, or question.
Е Л Трисветова (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: